R&G PharmaStudies Co., Ltd. (SHE:301333)

Market Cap	5.98B +36.5%
Revenue (ttm)	896.26M +21.2%
Net Income	133.65M -6.7%
EPS	1.40 -6.5%
Shares Out	95.99M
PE Ratio	44.45
Forward PE	36.01
Dividend	0.16 (0.26%)
Ex-Dividend Date	Jul 8, 2025

Volume	1,283,945
Average Volume	1,669,511
Open	62.00
Previous Close	62.30
Day's Range	60.35 - 62.20
52-Week Range	43.05 - 91.78
Beta	0.52
RSI	41.75
Earnings Date	Apr 28, 2026

About R&G PharmaStudies

R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company’s services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology services. It serves pharmaceutical and medical device companies, and scientific research institutions. The company was founded in 2008 and is headquarter...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 2,645
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301333

Financial Performance

In 2025, R&G PharmaStudies's revenue was 851.01 million, an increase of 14.38% compared to the previous year's 744.00 million. Earnings were 136.90 million, a decrease of -2.37%.